Document Detail


On the clinical evidence leading to tetrazepam withdrawal.
MedLine Citation:
PMID:  24845943     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Introduction: In July 2013, the European Medicines Agency suspended the marketing authorizations of tetrazepam across the European Union. Herein, we examine the various kinds of adverse drug reactions (ADRs) reported to be associated with tetrazepam. Areas covered: We undertook a two-sided systematic approach. First, we conducted a search in Medline for all studies that have published about tetrazepam ADRs in peer-reviewed journals. Second, we collected tetrazepam ADRs from pharmacovigilance system databases. Our study reveals discrepancies in the information provided by these two different sources, both in the number of cases reported as well as in the kind of reported ADRs. Whereas cutaneous alterations are the only ADRs reported in peer-reviewed journals, pharmacovigilance system databases include others (hepatobiliary, neurological and psychiatric). Expert opinion: We noted the lack of randomized controlled clinical trials evaluating tetrazepam efficiency and safety. We failed to find a turning point in the amount of ADRs reported following tetrazepam withdrawal to underpin the validity of the withdrawal. We stress the importance of a better communication of knowledge in scientific literature, pharmacovigilance agencies, and from doctors to prevent marketed usage of drugs with well-established side effects during long periods.
Authors:
Beatriz Proy-Vega; Carmelo Aguirre; Piet de Groot; Julián Solís-García Del Pozo; Joaquín Jordán
Related Documents :
23414133 - Spinal cord infarction following minor trauma in children: fibrocartilaginous embolism ...
15906603 - Traumatic axolemmal and cytoskeletal derangement in myelinated axons of human oedematou...
24044003 - Chordoid meningioma, part of a multiple intracranial meningioma: a case report & review.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  13     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2014 Jun 
Date Detail:
Created Date:  2014-05-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  705-12     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Selective synthesis of cis- and trans-2-methyl/phenyl-3-(trifluoromethyl)aziridines and their regio-...
Next Document:  Efficacy of antidepressant medications in children and adolescents with non-obsessive-compulsive dis...